Biotech Firms Fight Generics
Wall Street Journal — Brand-name drug companies are fighting to weaken a provision of the health overhaul that was designed to open up generic competition in biotechnology medicines and save billions of dollars.
The brand-name companies have drawn support from key lawmakers, raising alarms among generics makers who hoped to enter a huge market previously blocked to them.
"Biologic" drugs, which are proteins manufactured in living cells, account for some of the most lucrative products on the market and are increasingly used to treat difficult diseases such as cancer and rheumatoid arthritis.
